European life science and healthcare investor LSP has led a €32m Series B financing round for VarmX, a biotech company focused on developing approaches for the reversal of anticoagulation.
European life science and healthcare investor LSP has led a €32m Series B financing round for VarmX, a biotech company focused on developing approaches for the reversal of anticoagulation.